Evidence map›Paper›PMID 35777613›Full record

ArticleTransplant immunology2022

The effect of COVID 19 vaccination on kidney recipients.

Latifi Marzieh, Pourhosein Elahe, Rahban Habib, Pourhosein Maryam, Jafarian Arefeh, Eskandarzadeh Elnaz, Dehghani Sanaz

Open access · greenAbstract read
In one paragraph

Article in Transplant immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Latifi MarziehOrgan Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: marzieh.latifi@sbmu.ac.ir.
Pourhosein ElaheOrgan Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: elahepoorhosein1990@gmail.com.
Rahban HabibCardiovascular Research Foundation of Southern California, Beverly Hills, CA, USA; Southern California Medical Education Consortium, Temecula Valley Hospital, Universal Health System, Temecula, CA, USA. Electronic address: habib.rahban@uhsinc.com.
Pourhosein MaryamOrgan Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: zhino@tums.ac.ir.
Jafarian ArefehIranian Tissue Bank & Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: a_jafarian@sina.tums.ac.ir.
Eskandarzadeh ElnazOrgan Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: eskelnaz@gmail.com.
Dehghani SanazOrgan Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran; Iranian Tissue Bank & Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sanaz_dehghani2002@yahoo.com.
Sina Hospital · IRAja University of Medical Sciences · IRSouthern California Reproductive Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNearly one year from the onset of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, safe and effective vaccines began distribution around the world. This study aimed to assess the rate of COVID-19 disease among vaccinated kidney transplant patients and the types of symptoms found within them.

designThis cross-sectional study was performed at the transplant ward and Organ Procurement Unit of Sina Hospital, Tehran, Iran. As a sample size, 159 cadavers' kidney recipients received two doses of the Sinopharm SARS-CoV-2 vaccine. The required data were collected using a checklist via conducting a face-to-face interview.

resultsThe mean age of the vaccinated participants was 49.44 ± 13.87 years old. There were 73 (45.91%) vaccinated cases of SARS-CoV-2 infection during the study period, 18 cases (12.6%) occurred among fully vaccinated individuals, and 53 cases (33.3%) were among individuals who had received only one dose of vaccine. 45% of the fully vaccinated patients (received 2 doses vaccine) contracted SARS-CoV-2 from their families; 35% were infected through participation in social events (35%). There was a significant difference in disease severity levels between the fully vaccinated group and the one-dose vaccinated (p < 0.023). The severe disease occurred in 2 patients after vaccination, who were subsequently admitted to the hospital. There was a significant difference between the number of kidney transplant days and infection with SARS-CoV-2 before (P = 0.15) and after vaccination (p < 0.015).

conclusionEven after vaccination, kidney recipients are still at the risk of contracting SARS-CoV-2. In addition to these results, the efficacy of vaccination in preventing death caused by SARS-CoV-2 was confirmed.

Indexed as

COVID-19COVID-19 VaccinesTransplant RecipientsAdultCross-Sectional StudiesHumansIranKidneyMiddle AgedSARS-CoV-2VaccinationViral VaccinesCOVID-19 VaccinesViral VaccinesCadaveric donorKidney transplantationSARS-CoV-2 vaccine

Identifiers

PMID35777613
PMCPMC9238056
OpenAlexW4283697235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.